Search Results

Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Leerink Partners Biopharma Private Company Connect on Wednesday, June 26, 2024.

VYNE Therapeutics Inc. today announced members of VYNE’s management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation and Metabolic Diseases on Tuesday, July 9, 2024.

Nanoscope Therapeutics Inc. today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024.

Connect Biopharma Holdings Limited announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.

Cadrenal Therapeutics, Inc. will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Relmada Therapeutics, Inc. today announced that they will participate in the Leerink Partners Global Biopharma Conference.

Partner Therapeutics, Inc. announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency for the inhaled use of Leukine, branded in Japan as Sargmalin, to treat aPAP.